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The thioredoxin system, comprising thioredoxin (Trx), thioredoxin reductase (TrxR) and 
NADPH, is present in most organisms from prokaryotes to eukaryotes. The system plays a 
central role in the redox regulation of several key cellular processes including DNA 
synthesis, apoptosis, glycolysis and redox signal transduction and changes in this system are 
associated with the progression of a number of diseases including certain cancers, malaria 
and HIV. Understanding the regulation of this network from a systems perspective is 
therefore essential. Our lab developed the first computational model of the Escherichia coli 
thioredoxin system and analyzed this system using mathematical and core models. In contrast 
to the commonly held assumption of the thioredoxin network as an electrical circuit with no 
cross-talk, our analysis showed this system displayed ultrasensitivity, adaptability and was 
interconnected via the thioredoxin redox cycle. In this study, a model of the Saccharomyces 
cerevisiae thioredoxin system was developed and computational modeling showed that an 
increase in concentration of one of the substrates in the thioredoxin system could decrease the 
flux of another thioredoxin oxidation reaction in a concentration-dependent manner. To 
complement these computational analyses, yeast thioredoxin reductase and thioredoxin were 
cloned, expressed and purified. An in vitro kinetic assay using insulin as a substrate and 
immunoglobin Y (IgY) as a competing substrate was subsequently undertaken.  Our results 
showed that in some cases an increase in IgY concentration affected the rate of insulin 
reduction as measured by turbidity at 650 nm confirming the computational model's 
prediction. However, unexpectedly, with an increase in IgY concentration, there was a 
decrease in apparent absorbance at 650 nm at longer time points. These in silico and in vitro 
analyses shed light on how the thioredoxin system connects seemingly unrelated parts of 
metabolism into an integrated network, but additional experiments are required in order to 
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Chapter 1: LITERATURE REVIEW 
1.1 Introduction  
Cellular mechanisms that regulate redox homeostasis are vital as they provide a buffer 
against conditions that may disturb the redox environment of cells and induce oxidative stress 
(Schafer and Buettner, 2001; Perrone et al., 2008). The thioredoxin system is widely 
distributed among prokaryotes and eukaryotes, and plays a vital role in maintaining the redox 
homeostasis of the cell (Arnér and Holmgren, 2006). In this system, reducing equivalents are 
transferred from NADPH to thioredoxin by thioredoxin reductase (Fig. 1.1). Thioredoxin in 
turn reduces a large number of targets involved in several critical cell functions (Arnér and 
Holmgren, 2000a).  
 
Figure 1.1 Diagrammatic representation of the reactions and functions of the thioredoxin 
system. Reduced thioredoxin provides reducing equivalents to (i) thioredoxin peroxidase, which 
breaks down H2O2 to water, (ii) ribonucleotide reductase, which reduces ribonucleotides to 
deoxyribonucleotides for DNA synthesis, and (iii) transcription factors, which leads to their increased 
binding to DNA and altered gene transcription (Mustacich and Powis, 2000). 
This system was first discovered as an electron donor for the enzymatic synthesis of 
cytodine deoxyribonucleoside diphosphate by ribonucleotide reductase (RNR) from 
Escherichia coli (Laurent et al., 1964; Buchanan et al., 2012). Subsequently, E. coli 
thioredoxin was isolated, sequenced and was found to contain the now classic active site, -
2 
 
Cys-Gly-Pro-Cys- (Holmgren, 1968). E. coli thioredoxin reductase was also isolated and 
analysis of its kinetic properties showed that it was a specific reductant of thioredoxin (Moore 
et al., 1964).  
The thioredoxin system is essential for maintaining the balance of the cellular redox 
status and is involved in the regulation of redox signalling. Moreover, it is crucial for growth 
promotion, neuroprotection, inflammatory modulation, antiapoptosis, immune function 
(Mahmood et al., 2013). As an ubiquitous and multifunctional protein, thioredoxin is 
expressed in all forms of life, executing its function through its antioxidative, protein-
reducing, and signal-transducing activities (Lu and Holmgren, 2012). However, this system 
has been implicated in several human diseases such as cancer (Kim et al., 2003), malaria 
(Nickel et al., 2006), heart failure (Turoczi et al., 2003), neurodegenerative diseases 
(Lippoldt et al., 1995) and viral diseases such as human immunodeficiency virus (HIV) 
(Nakamura et al., 1996). Understanding the dynamics of this system using system biology 
approaches could be beneficial in the treatment of the above mentioned human diseases 
(D'Alessandro et al., 2011; Pillay et al., 2013).  
1.2 The yeast thioredoxin system 
The yeast, Saccharomyces cerevisiae contains a cytoplasmic thioredoxin system 
comprised of two thioredoxins (TRX1, TRX2) and a thioredoxin reductase (TRR1). Yeast also 
has a complete mitochondrial thioredoxin system comprised of the thioredoxin TRX3 and the 
thioredoxin reductase TRR2 which is thought to function in protection against oxidative stress 
generated during respiratory metabolism (Gan, 1991; Pedrajas et al., 1999). The cytoplasmic 
thioredoxins (TRX1, TRX2) and thioredoxin reductase (TRR1) are dispensable during normal 
growth conditions provided that a functional glutaredoxin/glutathione (Grx/GSH) system is 
present (Gan, 1991; Muller, 1991). These systems both belong to the thioredoxin superfamily 
whose members characteristically share the thioredoxin-fold. 
Yeast also contains two genes encoding cytoplasmic glutaredoxins (GRX1 and GRX2) 
which are also dispensable during normal growth provided that a functional thioredoxin 
system is present (Luikenhuis et al., 1997). The S. cerevisiae thioredoxin thiol redox system 
is therefore similar to that of E. coli as they both consist of the thioredoxin and 
glutathione/glutaredoxin pathways (Toledano et al., 2007) which are functionally overlapping 





Figure 1.2 Diagrammatic representation of the thioredoxin system. Reduced thioredoxin 
(Trx(SH)2) directly interacts with oxidized proteins (Protein ox) by reducing disulfide bridges. As a 
result, the target protein is reduced (Protein red) and thioredoxin itself is oxidized (TrxS2). The 
regeneration of thioredoxin from its oxidized form is catalyzed by thioredoxin reductase (TR) using 
NADPH (Lukosz et al., 2010). 
The first evidence that the thioredoxin and the glutathione/glutaredoxin systems share an 
overlapping function in redox regulation came from the identification of glutathione 
reductase (GLR) in a genetic screen for mutations which confer a requirement for 
thioredoxins (Muller, 1996). Furthermore, deletion analysis has shown that the quadruple 
yeast mutant (∆trx1∆trx2∆grx1∆grx2, Table 1.1) was not viable and a single functional 
disulphide reductase system is necessary for viability (Draculic et al., 2000). To further test 
the requirement for components of the thioredoxin and GSH systems, mutants lacking 
components of each system were constructed. Strains completely lacking the thioredoxin 
(∆trx1∆trx2∆trr1) or glutathione (∆gsh1∆glr1) systems were viable, but strains 
simultaneously deleted for components of both systems (∆gsh1∆trx1∆trx2 and ∆glr1∆trr1) 
were not viable. However, mutants lacking TRX1 and TRX2 (∆trx1∆trx2, Table 1.1) showed 
an increase in both oxidized GSSG and reduced GSH levels, together with an extended S-
phase (Muller, 1996; Garrido and Grant, 2002). The extended S-phase was caused by a 
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decrease in the dNTP pools due to an absolute decrease of the RNR reduced form and an 
increase of its oxidized disulfide bond form (Muller, 1996). The extended S-phase indicated 
that GRX1 and GRX2 were not as efficient as TRX1 and TRX2 in RNR reduction (Muller, 
1996). In summary, there is convincing evidence that these redox regulatory systems have 
many overlapping functions in terms of both regulation and substrate utilization. However in 
yeast, the thioredoxin system is more important in ribonucleotide reductase reduction. The 
properties of the individual components of the thioredoxin system will be described below. 
Table 1.1 Phenotypes of thiol redox systems in S. cerevisiae (Toledano et al., 2007) 
 
nl: Normal vegetative growth 
1.2.1 Thioredoxin reductase 
Thioredoxin reductase is the only known enzyme to maintain thioredoxin in a reduced 
state (Holmgren, 1985). Thioredoxin reductase is a member of a family of pyridine 
nucleotide disulfide oxidoreductases and members of this family are flavoproteins that 
contain one redox-active disulfide, one tightly bound flavin adenine dinucleotide (FAD) and 
an NAPDH binding site per subunit (Fig. 1.3; Williams, 1992), which is similar in the 
prokaryotes (archaea and bacteria) and eukaryotes such as yeasts (Kuriyan et al., 1991).        
S. cerevisiae TRR1 and TRR2 share a sequence identity of 85% (Fig. 1.4) and they both have 





Figure 1.3 Structure of Saccharomyces cerevisiae thioredoxin reductase (TRR1) dimer. FAD 
molecules, adenine ring and three phosphate groups of NADPH and the disulfides of active sites were 
drawn using a ribbon model (Zhang et al., 2009). 
Interestingly enough, activity assays indicated that Trr1 can also reduce S. cerevisiae 
thioredoxin-3 at a similar efficiency to that of Trr2 although they are located in different 
cellular compartments (Zhang et al., 2009). These results indicated that there was no 
selectivity within the S. cerevisiae thioredoxin system counterparts. This similar reductive 
efficiency was due to comparable kcat
app values (Table 1.2; Oliveira et al., 2010). 
 
Figure 1.4 Alignment of the amino acid sequences of S. cerevisiae Trr1 and Trr2. The redox-
sensitive motif is enclosed in a rectangle. Asterisks indicate identical residues. The sequence of Trr2 
was used as reference for the identity/similarity values. Alignments were made using ClustalX. 
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Table 1.2 Comparison of kinetic parameters for the reduction of yeast thioredoxins by 
thioredoxin reductase 1 (Trr1) (Oliveira et al., 2010) 
 
1.2.2 Thioredoxin 
Thioredoxin is a low molecular weight (12 kDa), thermostable protein and is present 
in all known living organisms (Holmgren, 1985). Thioredoxin can exist either in a reduced 
(thioredoxin-(SH)2) or oxidized form (thioredoxin-S2). The difference between these forms of 
thioredoxin involves a local conformational change in and around the redox-active disulfide 
(Arnér and Holmgren, 2000b). 
The oxidised form of thioredoxin contains a single redox active disulfide that is 
formed from the two half-cystine residues of the protein. In the presence of thioredoxin 
reductase and NADPH, this disulfide is opened and the reduced form of thioredoxin is 
subsequently formed (Hall et al., 1971). This active form of thioredoxin becomes reoxidized 
while providing reducing equivalents to target molecules including ribonucleotide reductase, 
thioredoxin peroxidase and transcription factors (Fig. 1.1-1.2; Mustacich and Powis, 2000). 
S. cerevisiae contains three thioredoxin isoforms. Thioredoxin-1 and thioredoxin-2 are 
cytosolic thioredoxin proteins and thioredoxin-3 is located in the mitochondria and is much 
larger than both thioredoxin-1 and thioredoxin-2 (Pedrajas et al., 1999). TRX1 and TRX2 
share 78% amino acid identity, and 46% (TRX1) and 43% (TRX2) identity relative to TRX3 
(Fig. 1.5; Pedrajas et al., 1999). 
The role of the thioredoxin system in certain disease pathogenesis states and the effect 
on the cellular redox balance in lung cancer and human immunodeficiency virus (HIV) are 
discussed below. 
Substrate KMapp (μM) kcatapp (s-1) kcat/KMapp (1/μMs-1) 
Yeast  thioredoxin-1-TRR1 1.3 ± 0.2 43.7 ± 2.5 (3.4 ± 1.2) × 107 
Yeast  thioredoxin-2-TRR1 0.6 ± 0.1 42.9 ± 1.5 (7.3 ± 1.5) × 107 




Figure 1.5 Alignment of the amino acid sequences of S. cerevisiae thioredoxin-1, thioredoxin-2, 
and thioredoxin-3. The redox active site is enclosed in a rectangle.  Asterisks indicate identical 
residues. The sequence of thioredoxin-3 was used as reference for the identity/similarity values. 
Alignments were made using ClustalX (Pedrajas et al., 1999).                                                    
1.3 The thioredoxin system and disease 
1.3.1 Cancer 
Arnèr and Holmgren (2006) reviewed numerous scientific reports describing higher 
expression of thioredoxin and thioredoxin reductase in certain cancer tumors. For example, 
thioredoxin expression is increased in several primary cancers, including lung (Kim et al., 
2003; Xu et al., 2012), cervix (Hedley et al., 2004), pancreatic (Han et al., 2002), colorectal 
(Raffel et al., 2003), hepatocellular carcinomas (Miyazaki et al., 1998), gastric carcinomas 
(Grogan et al., 2000) and breast cancer (Cha et al., 2009). Data also suggests that the high 
thioredoxin concentrations could be linked to resistance to chemotherapeutic agents including 
doxorubicin, cisplatin, docetataxel and tamoxifen (Karlenius and Tonissen, 2010). In one 
study for example, tumors with high thioredoxin expression showed a significantly lower 
response rate to docetaxel than those with low thioredoxin expression (Marks, 2006). In 
another study, gene expression profiling of 44 breast tumor samples treated with docetaxel 
and were analyzed. It was found that nearly half of the docetaxel resistant cells were 
characterized by elevated expression of redox genes, including glutathione S-transferase, 
peroxiredoxins and thioredoxin (Iwao-Koizumi et al., 2005). Furthermore, resistance of 
ovarian, gastric and colon cancer cells has been associated with increased intracellular 
thioredoxin levels (Marks, 2006; Yoshioka et al., 2006). These studies suggested that 
thioredoxin levels were elevated in many human primary cancers and this high expression 
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was associated with aggressive tumor growth and inhibited apoptosis (Karlenius and 
Tonissen, 2010). 
1.3.2 Human Immunodeficiency Virus (HIV) 
Elevated levels of the thioredoxin system have also been implicated and are indicative 
of oxidative stress during HIV infection (Pace and Leaf, 1995; Gromer et al., 2004). These 
elevated levels have been reported in the chronic stages of HIV-1 infection and may facilitate 
virus entry in macrophages (Stantchev et al., 2012). This was shown in a study where HIV-
infected individuals had elevated levels of thioredoxin and displayed lower CD4+ cell counts 
(Nakamura et al., 2001). These HIV-infected individuals showed increased plasma/serum 
levels of thioredoxin and patients with higher plasma thioredoxin die sooner than patients 
with normal plasma levels of thioredoxin (Nakamura et al., 2001; Van Laer et al., 2002). 
However, elevated levels of thioredoxin do not necessarily indicate advanced HIV-infection 
as thioredoxin levels were shown to have been elevated in some apparently healthy HIV-
infected people (Nakamura et al., 1996). 
In contrast to the serum levels, lymph node biopsies of HIV-patients showed a 
significant loss of thioredoxin-production in this tissue (Gromer et al., 2004). In addition, 
thioredoxin was also shown to be deficient in tissues from acquired immune deficiency 
syndrome (AIDS) patients (Nakamura et al., 1996). This may be explained by the ability of 
macrophages to convert thioredoxin into the C-terminally truncated 10 kDa protein called 
eosinophil cytotoxicity-enhancing factor (ECEF) (Fig. 1.6) which enhances HIV-production 
(Newman et al., 1994). Thus, whereas thioredoxin is a potent inhibitor of the expression of 
HIV in human macrophages, cleavage of thioredoxin to ECEF creates a mediator with the 




Figure 1.6 Schematic representation of the interaction of thioredoxin, ECEF and HIV-
production.  Indicated are theoretical therapeutic approaches. Trx80 is a 10 kDa truncated form of 
thioredoxin containing the 80 N-terminal residues. White arrows indicate stimulation and dark arrows 
indicate inhibition (Gromer et al., 2004). 
1.3.3 Malaria 
While changes in the human thioredoxin system are implicated in several diseases, a 
number of pathogens also rely on their thioredoxin systems to overcome oxidative stresses 
generated during host infection. These pathogens include Plasmodium falciparum (Holmgren 
and Lu, 2010) and Trypanosomatid protozoa (Krauth-Siegel and Comini, 2008). 
P. falciparum, the protozoan parasite responsible for a million clinical malaria cases, 
is dependent on the antioxidant capacity of its host cell and its own peroxidases which both 
require the thioredoxin system to function (Nickel et al., 2006). Although the parasite 
possesses a glutathione peroxidase and a thioredoxin system, the host thioredoxin system is 
proposed to be the main detoxification system for reactive oxygen species (Adelekan et al., 
1998). It has been demonstrated that the human redox protein peroxiredoxin-2 is imported 
from the host erythrocyte into the cytosol of P. falciparum in functional form and in 
significant concentrations (Koncarevic et al., 2009). This result provided insights into the 
interaction between malarial parasites and their host cells. Thus, instead of depleting its own 
resources, P. falciparum makes use of human peroxiredoxin-2 for its own survival 
(Koncarevic et al., 2009).  
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However, efforts at combating these above mentioned pathologies have been limited 
by the complexity of the thioredoxin system (Jones, 2010). As a result, analyzing the 
thioredoxin system and its regulation using a systems biology approach is required in order to 
acquire a clearer understanding of the integrated regulation and dynamics of the elements in 
this system (Kemp et al., 2008). This could be beneficial in the treatment of these pathologies 
in which redoxins are implicated.  
1.4 Systems biology 
The kinetics of individual thioredoxin-dependent reactions has been thoroughly studied. 
However, the kinetic regulation of the thioredoxin system as a whole is not yet known and 
there is not yet a complete theoretical frame work to base systems analysis on (Pillay et al., 
2009). Although the thioredoxin system has an effect on several processes (Fig. 1.2), it was 
initially not clear whether thioredoxin-dependent reactions have an effect on each other and 
how the kinetic structures within the thioredoxin system contribute to the regulation of the 
system (Pillay et al., 2009). This question has been addressed by using kinetic modeling to 
identify and describe the kinetic behaviors found within the system (Pillay et al., 2011).  
Two modeling approaches have since been developed to describe the behavior or activity 
of the thioredoxin system (Kemp et al., 2008; Pillay et al., 2011). In the first approach, 
thioredoxin is considered an enzyme and forms part of an electron circuit incorporating the 
major cellular redox couples (Kemp et al., 2008). The steady-state redox values for these 
couples are maintained separately for each couple by the balance of NADPH-dependent 
reduction and peroxide-dependent oxidation rates. This implies that each redox couple can be 
used for different redox-control processes independently (Kemp et al., 2008). The second 
model proposed that thioredoxins are redox couples and thioredoxin-dependent reactions 
affect each other through the thioredoxin redox cycle (Pillay et al., 2011). However, these 
results were obtained solely from computational analysis and it is not known whether the 
system displays this behaviour in vitro and in vivo. 
The two different modelling approaches are shown below (Fig. 1.7). The one approach 
(darker arrows on the left) represents the electron flow modeling approach of the thioredoxin 
system (Kemp et al., 2008). In this approach, each couple is used for different redox-control 
processes (Kemp et al., 2008) with the reactions independent of one another, but are all 
dependent on the NADPH concentration. In contrast, the thioredoxin redoxin couple 
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approach focused on the kinetics of individual thioredoxin-dependent reactions in the system 
(Fig. 1.7; Pillay et al., 2011), with the thioredoxin reductase and individual thioredoxin 







                                                   
Figure 1.7 Modelling the thioredoxin system in E. coli. Shows reactions for reduction of oxidised 
thioredoxin (TrxSS) by thioredoxin reductase (TR), thioredoxin-dependent reductions of methionine 
sulfoxide (Met-S-SO) by methionine sulfoxide reductase (MsrA) and 3'-phosphoadenosine-5'-
phosphosulfate (PAPS) by PAPS reductase and the Tpx-dependent reduction of hydrogen peroxide 
(Pillay et al., 2011).  
1.5 Aims 
Analyzing the dynamics of the thioredoxin system through the use of system biology 
approaches could prove to be useful for the quantification and understanding of the regulation 
of these systems in cells. An important step would be to distinguish between the redox couple 
and the electron flow models in vitro. However, there are limitations that need to be 
considered and addressed in order to complete these studies. Current activity assays require 
thioredoxin and thioredoxin reductase to be in a purified form. Therefore, yeast thioredoxin 
and thioredoxin reductase needed to be cloned, expressed and purified. In addition, we had to 
develop an assay to monitor the effect of two thioredoxin substrates on the dynamics of the 
system in order to distinguish between the redox couple and the electron flow models. 
12 
 
Chapter 2: GENERAL MATERIALS AND METHODS 
General methods and materials that were regularly used throughout the duration of this 
research project are presented in this section. 
2.1 Materials 
Agarose used for gel electrophoresis was purchased from Whitehead Scientific Pty 
Ltd (Cape Town, South Africa) and ethidium bromide was purchased from Promega. 
Acrylamide-Bis readymade solution (37.5:1) and bromophenol blue were purchased from 
Merck (South Africa). Ammonium persulfate, Coomassie brilliant blue G-250 powder, 
bovine serum albumin (BSA) and N,N,N',N'-tetramethylethylenediamine (TEMED) were all 
purchased from Sigma (Capital Labs, South Africa). Distilled water and ultrapure water were 
both obtained from the Milli-Q Plus UF Ultra-Pure Water System (UKZN). Ethanol and 
glycerol were obtained from Saarchem (Merck, South Africa). 
2.2  Quantifying DNA concentration and quality 
Quantitation of nucleic acids was routinely performed to determine the concentration 
of DNA or RNA present in a mixture, as well as their purity. Two methods were used to 
establish the concentration and quality of a solution of nucleic acids namely 
spectrophotometric quantification and UV fluorescence in presence of a DNA dye. 
2.2.1  Nanodrop 
The Thermo Scientific NanoDrop 2000 UV-Vis Spectrophotometer was used for 
quantification of nucleic acid concentration (ng/µl) and determining its purity. A minimum    
of 1 µl was pipetted on the lower optical surface of the NanoDrop. Upon closing of the 
spectrophotometer arm, a liquid column was created between the upper and lower optical 
pedestal by surface tension. Nucleic acid concentration was measured following blanking the 
spectrophotometer with TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)).  
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2.2.2 Agarose gel electrophoresis 
Preparation of reagents 
2.2.2.1  50X TAE [1X solution: 0.04 M Tris, 0.02 M acetic acid, and 0.001 M EDTA] 
A stock solution of 50X TAE was made by dissolving Tris (48.4 g), glacial acetic acid 
(11.42 ml) and 0.5 M EDTA (20 ml) (pH 8.0) in 200 ml dH2O.  
2.2.2.2  DNA loading buffer [30% (v/v) glycerol, 0.25% (m/v) bromophenol blue] 
The DNA loading buffer was made by adding bromophenol blue (0.025 g) to 3.75 ml 
of 80% glycerol. The volume was made up to 10 ml with dH2O.  
2.2.3 Method 
To analyse the DNA samples (plasmid DNA, restriction digests and PCR products) 
generated in this study, agarose gel electrophoresis was used. In this procedure,                     
agarose (1%) was completely dissolved in 1X TAE buffer in a microwave. Once the                                  
gel had cooled to approximately 45oC, ethidium bromide was added to a final                                             
concentration of 0.5 µg/ml and the mixture was poured on a casting tray to set. The gel was                                         
electrophoresed (100 V, 40 min) until the bromophenol blue in the loading dye had migrated 
over halfway down the gel and was then viewed under UV transilluminator for analysis of 
DNA fragments. A standard curve of log molecular weight against the distance travelled by 
each fragment (cm) was plotted and band size was determined by extrapolation.  
2.3 Measuring protein concentration 
2.3.1 Bradford assay 
The Bradford dye-binding assay is a quantitative method for the determination of 
protein concentration (Bradford, 1976). This method is based on the binding of Coomassie 
brilliant blue G-250 dye to basic amino acid side chains. The binding reaction causes a shift 
in the absorbance maximum of the dye from the cationic red at 465 nm to the anionic blue 
form at 595 nm (Compton and Jones, 1985). The intensity of the coloured reaction product is 
a direct function of protein concentration which can be determined by comparing its 
absorbance value to a standard curve. 
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Preparation of reagents 
2.3.1.1 Standard Bovine serum albumin solution [1 mg/ml] 
Bovine serum albumin (0.01 g) solution was dissolved in 10 ml of dH2O. 
2.3.1.2 Perchloric acid [2% v/v] 
Perchloric acid (27.8 ml) was made up to 1 liter with dH2O. 
2.3.1.3 Bradford dye reagent 
Perchloric acid (2% v/v) (1000 ml) was used to dissolve 0.6 g of Coomassie brilliant 
blue G-250. This was stirred for 1 hour and filtered through Whatman No. 1 filter paper and 
the resulting solution was stored in amber colored bottles.  
2.3.2 Method 
A standard protein concentration curve was constructed using bovine serum albumin 
ranging in concentration from 0 to 100 μg (0 – 100 μl) in Bradford reagent (to a final volume 
of 1 ml). The absorbance of all the solutions was measured at 595 nm after a 5 minute room 
temperature incubation period. This experiment was replicated in triplicate and a standard 
curve was generated (R2 = 0.9941). 
2.4 Tris-Tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Tricine SDS-PAGE was intended for the resolution of smaller proteins which are 
sometimes poorly resolved by the commonly used Laemmli SDS-PAGE. In this system, 
tricine and the higher pH of the stacking gel caused the mobility of the protein relative to the 
trailing ion to increase, allowing for the separation of low molecular weight protein SDS 
complexes (Schägger and von Jagow, 1987). The protein products were made visible by the 
Coomassie Blue G-250 or Bradford reagent, which is the most common used anionic staining 
dye for proteins in SDS-PAGE gels (Dennison, 2003). Proteins in the gel were fixed by acetic 
acid and simultaneously stained. The excess dye incorporated into the gel could be removed 
by destaining with the same solution without the dye (Dennison, 2003). The proteins were 
detected as blue bands on a clear background.  
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Preparation of reagents 
2.4.1.1 SDS [10% m/v] 
SDS (10 g) was dissolved in dH2O and made up to 100 ml. 
2.4.1.2 Gel buffer [3 M Tris-HCl, 0.3% (m/v) SDS, pH 8.45] 
Tris (72.7 g) was dissolved in dH2O (200 ml) and adjusted to pH 8.45 with HCl.    
10% (m/v) SDS (6 ml) was added and the solution was made up to 250 ml. 
2.4.1.3 Anode buffer [0.2 M Tris-HCl, pH 8.9] 
Tris (24.22 g) was dissolved in 950 ml of dH2O, adjusted to pH 8.9 with HCl and 
made up to 1 liter. 
2.4.1.4 Cathode buffer [0.1 M Tris-HCl, 0.1 M Tricine, 0.1% (m/v) SDS, pH 8.25] 
Tris (12. 1 g), Tricine (17.9 g) and 10% (m/v) SDS (10 ml) were made up to 800 ml 
with dH2O the pH adjusted if necessary and made to a final volume of 1 liter.  
2.4.1.5 Treatment buffer [125mM Tris-HCl, 4% (m/v) SDS, 20% (v/v) glycerol,         
10% (v/v) 2-mercaptoethanol, 0.01% (m/v) bromophenol blue, pH 6.8] 
Stacking gel buffer (2.5 ml), glycerol (2 ml), 10% (m/v) SDS (4 ml),                            
2-mercaptoethanol (1 ml) and bromophenol blue 0.01% (m/v) were made up to 10 ml with 
dH2O. Samples were boiled for 3 minutes in treatment buffer before electrophoresis. For non-
reducing SDS-PAGE, 2-mercaptoethanol was not added.  
2.4.1.6 Ammonium persulfate (APS) [10% (m/v)] 
Ammonium persulfate (0.1 g) was made up to 1 ml with dH2O. This solution was 
prepared before use. 
2.4.1.7 Coomassie blue stain [0.125% (m/v) Coomassie brilliant blue G-250, 50% (v/v) 
methanol, 10% (v/v) acetic acid] 
Coomassie brilliant blue G-250 powder (0.25 g), methanol (100 ml) and acetic       
acid (20 ml) were made up to 200 ml with dH2O. 
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2.4.1.8 Destain I [50% (v/v) methanol, 10% (v/v) acetic acid] 
Methanol (500 ml) and acetic acid (100 ml) were made up to 1 liter with dH2O. 
2.4.1.9 Destain II [5% (v/v) methanol, 7% (v/v) acetic acid] 
Methanol (25 ml) and acetic acid (35 ml) were made up to 500 ml with dH2O. 
2.4.2 Method 
The running gel consisted of dH2O (5.05 ml), monomer solution 12.5% (v/v)        
(6.67 ml), gel buffer (4.0 ml), APS (0.016 ml) and TEMED (0.240 ml). This solution was 
poured between the glass plates and immediately overlaid with a layer of dH2O and allowed 
to polymerise for 1 hour at room temperature. After polymerization, the layer of dH2O was 
removed and the running gel was overlaid with stacking gel which consisted of dH2O        
(3.0 ml), monomer solution 4% (v/v) (0.67 ml), gel buffer (1.25 ml), APS (0.010 ml) and 
TEMED (0.050 ml)]. Samples were mixed with an equal volume of treatment buffer, boiled 
for 3 minutes and loaded. Electrophoresis was performed at a constant current of 43 mA until 
the dye had migrated to the bottom of the gel. The gels were stained in Coomassie brilliant 
blue staining solution (section 2.4.1.7 below) overnight and subsequently destained in destain 
I (section 2.4.1.8) and destain II (section 2.4.1.9). After electrophoresis, the gels were soaked 
in Coomassie blue stain in plastic containers at room temperature and left overnight on a 
laboratory shaker. The following day, the Coomassie stain was then poured out and the gels 
were soaked in destain I until the gel background was clear. The gels were then soaked in 






Chapter 3: CLONING AND PURIFICATION OF 
THIOREDOXIN AND THIOREDOXIN REDUCTASE 
3.1 Introduction 
The main challenge of isolating a protein is to choose an activity assay that can 
measure the presence of the protein and also distinguish it from all other proteins that may be 
present in the same sample (Dennison, 2003). For thioredoxin, the turbidimetric insulin 
reduction assay using either DTT or thioredoxin reductase/NADPH as reducing equivalent 
donors is used (Holmgren, 1979; Arnér and Holmgren, 2000b). In this assay, the initial 
velocity of the insulin reduction is derived from the linear part of the increase in absorbance 
at 650 nm. For thioredoxin reductase, the colorimetric reduction of 5,5′-dithiobis (2-
nitrobenzoic) acid (DTNB) to 5-thio-2-nitrobenzoic acid (TNB) produces a strong yellow 
color at 412 nm which is measured. DTNB is very useful as a sulfhydryl assay reagent 
because of its specificity for thiol groups at neutral pH, high molar extinction coefficient and 
short reaction time (Lim and Lim, 1995). 
The next challenge in protein purification is to determine a strategy for isolating the 
protein of choice. The method used by Seo and Lee (2010) involved three steps: ammonium 
sulfate fractionation, 2' 5' ADP-sepharose affinity chromatography and Sephadex G-100 
column chromatography.  The final choice in conventional protein purification strategy is 
usually a compromise between maximum recovery and maximum purity. However, one 
straightforward way to achieve both maxima is to fuse the target gene to a promoter which 
drives expression of any gene placed under its control. Furthermore, this approach allows the 
protein to be tagged by a His-tag, for example, to facilitate purification (Reece, 2004). The 
former approach was used when Kim et al. (2005) who cloned TRR1 into pET-17b 
expression vector and subsequently induced expression of TrxR with IPTG in E. coli BL21 
cells. TrxR was subsequently purified by diethyl aminoethyl (DEAE) and phenyl 
hydrophobic chromatography. Similarly, Oliveira et al. (2010) cloned TRR1 into pPROEX-1 
expression vector using the BamHI-NdeI restriction sites and purified by nickel affinity 
chromatography.   
As thioredoxin is thermostable, most purification procedures make use of a heat 
treatment which results in the denaturation of most of the undesired proteins. This is then 
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subsequently followed by centrifugation and chromatography to complete the purification 
process. Methods implemented by Williams et al. (1967) in the purification of thioredoxin 
involved RNase A, protamine sulfate and ammonium sulfate treatments and associated 
centrifugation steps. Harms et al. (1998) were able to purify the redoxin in four basic steps 
which were DEAE-Sephacel anion-exchange chromatography, acid treatment with HCl, 
affinity chromatography with Procion Red and gel-permeation chromatography. Yoshiharu et 
al. (2007) were able to extract thioredoxin from S. cerevisiae cultured with 20% ethanol 
which appeared to be a promising method in thioredoxin extraction. However, because 
thioredoxin makes up just 0.015% of all soluble protein in yeast (Porqué et al., 1970) this 
procedure compromised maximum protein recovery (Padayachee, 2013). 
In contrast, Wang et al. (2009) cloned TRX1 into pLM1 expression vector using the 
EcoR1-Sal1 restriction sites and the resulting pLM1::TRX1 plasmid was sequenced to 
confirm that the construction was correct. The induced E. coli cells containing the 
pLM1::TRX1 plasmid were grown and were subsequently lysed and centrifuged. The final 
step of purification involved the clear supernatant being applied to a Hi-Trap column. 
Similarly, the TRX1 PCR product has also been directly cloned into NotI and NdeI restriction 
sites of the pET28b expression vector and subsequently protein expression induced with 
IPTG (Zhang et al., 2008). Purification of the protein was done by Ni2+ affinity column 
chromatography and the purity of protein was confirmed by SDS-PAGE. Miranda-Vizuete et 
al. (1997) used a TA cloning approach and acquired the TRX2 gene by PCR and directly 
ligated it into the cloning vector pGEM-T. The NdeI-BamHI TRX1 fragment from this vector 
was subsequently sub-cloned into the pET-15b expression vector system. The protein was 
purified by applying the clear supernatant from the lysed centrifuged cells through a Hi-Trap 
column. The materials and methods used to isolate and purify components of the thioredoxin 
systems for subsequent kinetic analysis are described below. 
3.2  Materials and methods 
3.2.1 Materials 
RNase A was obtained from Roche (South Africa). The Thermo Scientific Rapid 
DNA Ligation Kit, Fermentas Gel Extraction Kit, InsTAcloneTM PCR cloning kit, 
TransformAidTM Bacterial Transformation Kit, 100 bp plus and 1 kbp Molecular Weight 
Markers and TaqTM DNA polymerase were obtained from Inqaba Biotech (Johannesburg, 
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South Africa). Kanamycin, ampicillin and Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
were from Sigma (Capital Labs, South Africa) while the QIAquickTM Gel Extraction Kit and 
Ni-NTA agarose were from Whitehead Scientific (Pty) Ltd (Cape Town, South Africa). The 
New England Biolabs restriction enzymes HindIII, NdeI and BamHI were obtained from The 
Scientific Group (Midrand, South Africa). Escherichia coli BL21 (DE3) and DH5α cells 
were acquired from Megan Brunkhorst (Genetics, UKZN). The expression vector, pET28a, 
was from the Biochemistry department (UKZN) and the thioredoxin clones (LPTRXA and B) 
were generously supplied by Miss L. Padayachee (PhD candidate, UKZN). All other 
common reagents were obtained from Saarchem (Merck, South Africa). 
3.2.2 Preparation of reagents 
3.2.2.1 Kanamycin [30 mg/ml] 
Kanamycin sulphate (0.3 g) was dissolved in dH2O and the volume was made up to 
10 ml. The suspension was sterilized filtering through a 0.2 μm filter and stored in 1 ml 
aliquots at -20oC.  
3.2.2.2 Ampicillin [25 mg/ml] 
Ampicillin sodium salt (0.25 g) was dissolved in dH2O and the volume was made up 
to 10 ml. The suspension was sterilized by passing it through a 0.2 μm filter and stored 
in 1 ml aliquots at -20°C. 
3.2.2.3 Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
IPTG powder (0.238 g) was dissolved in dH2O and the volume was made up to 10 ml. 
This suspension was sterilized by passing it through a 0.2 μm filter and stored in 1 ml 
aliquots at -20oC. 
3.2.2.4 Luria Bertani (LB) agar 
Yeast extract 0.5% (w/v), tryptone 1% (w/v), NaCl 0.5% (w/v) and bacteriological 
agar 1.5% (w/v) were dissolved in dH2O and the solution was made up to the desired volume. 
The solution was autoclaved and allowed to cool. Kanamycin (30 μg/ml) or ampicillin 
(100 μg/ml) was added to the required final concentration and plates were then poured and 
stored in the fridge at 4°C. 
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3.2.2.5 Luria Bertani (LB) broth 
Tryptone 1% (w/v), NaCl 0.5% (w/v) and yeast extract 0.5% (w/v) were dissolved in 
dH2O and the solution was made up to the desired volume. The solution was autoclaved and 
allowed to cool. Kanamycin (30 μg/ml) or ampicillin (100 μg/ml) was added to the required 
final concentration. 
3.2.2.6 SOC media 
Tryptone 2% (w/v), yeast extract 0.5% (w/v), MgCl2 (10 mM), NaCl (10 mM) and 
KCl (2.5 mM) were dissolved in dH2O and the solution was made up to the desired volume. 
The solution was autoclaved and cooled. Glucose was added to the desired final 
concentration [20 mM]. Prior to addition, the glucose stock solution (1 M) was sterilized by 
filtration through a 0.2 μm filter. The SOC media was stored at 4°C. 
3.2.2.7 2xYT media 
Tryptone 1.6% (w/v), yeast extract 1% (w/v) and NaCl 0.5% (w/v) were dissolved in 
dH2O. The pH was adjusted to 7.0 with NaOH and the volume was made up with dH2O. The 
solution was sterilized by autoclaving and thereafter stored at room temperature.  
3.2.2.8 Yeast Peptone Dextrose (YPD) 
Peptone 2% (w/v), dextrose 2% (w/v) and yeast extract 1% (w/v) were dissolved in 
dH2O and the solution was made up to the desired volume and the solution was autoclaved. 
3.3 Methods 
3.3.1 Cloning of TrxR 
The following methods where used for cloning of TrxR. 
3.3.1.1 Isolation of yeast genomic DNA 
Genomic DNA from Saccharomyces cerevisiae was extracted from 4 x 1.5 ml 
overnight cultures grown in YPD using the Bust ‘n Grab method (Harju et al., 2004). The 
overnight cultures were pelleted (20, 000 x g for 5 minutes, room temperature) and the pellet 
was re-suspended in lysis buffer (2% (v/v) Triton X-100, 1% (w/v) SDS, 100 mM NaCl,      
10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (pH 8.0)) by gentle inversion of the tubes or 
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brief vortex if needed. Sequential rapid freeze-thaw steps (-75oC for 5 minutes and 95oC 
water bath for a minute) were followed by 30 seconds of vortexing. Chloroform (200 µl) was 
added to the tubes followed by 2 minutes of vortexing. The tubes were centrifuged (20, 000 x 
g, 5 minutes, room temperature) and three distinct layers could be seen. The upper aqueous 
phase was transferred into a clean eppendorf tube containing 400 µl ice-cold 100% (v/v) 
ethanol. The tubes were inverted and incubated for 5 min at -20°C in order to precipitate the 
DNA. The precipitated DNA was pelleted by centrifugation (20, 000 × g, 5 minutes, room 
temperature), washed with 70% (v/v) ethanol (0.5 ml) and air-dried. The pellets were re-
suspended in 50 µl TE buffer [1 mM EDTA (pH 8.0), 10 mM Tris-HCl (pH 8.0)] and the 
samples were assayed by the Nano Drop 2000 UV-Vis Spectrophotometer and agarose gel 
electrophoresis to determine DNA concentration and purity. 
3.3.1.2 PCR 
3.3.1.2.1 Plasmid and genomic DNA 
To amplify the TRR1 gene from genomic DNA and to confirm the                     
identity of the plasmid DNA, PCR was performed using yeast                                                                  
TRR1 specific primers, 5'-AGCCATATGGTTCACAACAAAGTTAC-3'  and          
5'-ACGAAGCTTATTCTAGGGAAGTTAAGT-3' (NdeI and HindIII sites are underlined) 
which were designed using Primer3 (http://frodo.wi.mit.edu). The PCR reaction mixture 
consisted of TaqDNA polymerase (0.5 U), reaction buffer (1X), a dNTP mix (0.2 mM), the 
forward and reverse primers (250 nM each) and plasmid or genomic DNA (0.01-1 µg) in     
25 µl. The following PCR cycling conditions were used: 94°C, 1 min (initial denaturation); 
94°C, 30sec; 46°C, 30 sec; 72°C, 1 min (35 cycles) and a final extension of 72°C, 5 min. A 
no template control was included in order to check for contamination and the PCR products 
were analyzed by agarose gel electrophoresis (100 V, 65 A; Section 2.2.2). 
3.3.1.2.2 Colony PCR 
Small sections of the single colonies from different test plates were selected, 
dissolved in autoclaved dH2O (25 µl) and incubated in a water bath (2 min, 100oC). The tubes 
were centrifuged (13, 000 × g, 2 min, room temperature) and 2 µl of the supernatant was used 
to perform a PCR as described above (section 3.3.1.2.2).   
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3.3.2 Plasmid DNA purification 
Plasmid DNA was purified using a standard mini-prep procedure (Sambrook et al., 
1989). Four 10 ml samples of an overnight culture grown in LB containing the appropriate 
antibiotic were centrifuged (7250 × g, 5 min, 4°C) and the pellet was re-suspended in 200 μl 
GTE solution (25 mM Tris-Cl (pH 8.0), 10 mM EDTA, 50 mM glucose). RNase A (2 μg/ml) 
was then added and the suspension was incubated at room temperature for 5 min and 
subsequently transferred into a sterile eppendorf tube. 400 μl of a NaOH/SDS solution             
(0.2 M NaOH, 1% (w/v) SDS) was added to lyse the cells and the suspension was mixed by 
gentle finger tapping followed by incubation on ice for 5 min. A 3 M potassium acetate              
solution (300 μl) was added and the suspension was incubated on ice for 5 min before being 
centrifuged (12 000 x g, 5 min, room temperature). Isopropanol (600 μl) was added to the 
supernatant (800 μl) which was incubated at -20°C for 30 min. The suspension was 
centrifuged (12 000 × g, 5 min, room temperature) and the pellet was washed with ice-cold 
70% ethanol (500 μl). The pellet was then re-suspended in 50 µl TE buffer (10 mM Tris-HCl 
(pH 8.0), 1 mM EDTA (pH 8.0)). These samples were assayed using a Nano Drop 2000     
UV-Vis Spectrophotometer and by agarose gel electrophoresis to determine DNA 
concentration and purity.  
3.3.3 Restriction digestion 
Plasmid DNA was routinely restricted with BamHI or HindIII to linearize the DNA 
for sizing. In these reactions, plasmid DNA (1 µg), restriction enzyme (1 U) and buffer were 
incubated at 37oC for 1 hour. For cloning experiments, plasmid DNA was restricted with 
HindIII and NdeI to liberate the TRR1 fragment. In these reactions, plasmid DNA               
(240 ng/µl), restriction enzyme (1 U each) nuclease free water and BSA (4 µg/µl) were all 
incubated with 1X NEBuffer 2 at 37oC for 3 hours. 
3.3.4 Gel purification of the TRR1 insert and pET28a vector 
Restriction digested pET28a and the liberated TRR1 fragment were both gel purified 




3.3.5 Ligation of TRR1 insert into plasmid vectors 
A typical ligation mixture contained vector DNA (10 – 100 ng), insert DNA (at 3: 1 
molar excess over vector), 1X Rapid Ligation Buffer, T4 DNA ligase (5U/µl) and nuclease 
free water. The mixture was then incubated at room temperature for an hour followed by an 
overnight incubation at 4oC and was then used for transformation. 
3.3.5.1 InsTAcloning T-vector 
The pTZ57R/T vector was transformed into E. coli JM109 cells using the 
TransformAidTM Bacterial Transformation Kit according to the manufacturer’s instructions 
and yielded clones (pTRRA, B, C, and D). As a positive control for competent cell growth,   
E. coli JM109 competent cells were plated onto LB agar plate with no antibiotic and as a 
negative control, untransformed cells were plated onto LB plates containing ampicillin 
(100 µg/ml). In order to purify the recombinant pTZ57R/T DNA, a plasmid mini-prep 
procedure was (section 3.3.2). 
3.3.5.2 pET28a 
The gel-extracted TRR1 fragment and restricted pET28a expression vector were 
ligated (section 3.3.5) to form the expression plasmids pMTRA, B, C and D using a Rapid 
DNA Ligation Kit and this was plated onto LB agar plates containing kanamycin (30 µg/ml).            
As a positive control for competent cell growth, E. coli BL21 (DE3) competent            
cells (section 3.3.6.1) were plated onto LB agar plates with no antibiotic and as a negative 
control, untransformed cells were plated onto LB plates containing kanamycin (30 µg/ml). In 
order to purify the recombinant DNA (pMTRA – D), a plasmid mini-prep procedure was 
performed as per section 3.3.2. 
3.3.6 Transformation 
3.3.6.1 Generation of competent cells (CaCl2) 
A calcium chloride (CaCl2) method was used to make E. coli BL21 (DE3) competent 
cells (Sabel'nikov et al., 1977). E. coli BL21 (DE3) cells were grown in 2xYT medium 
(Tryptone 1.6% (w/v), yeast extract 1% (w/v) and NaCl 0.5% (w/v)) until an OD600 0.3-0.4 
was reached. Four 10 ml samples were transferred to ice-cold sterile tubes, incubated on ice 
for 10 min and thereafter centrifuged (4500 × g, 10 min, 4°C). The pellet was re-suspended in 
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ice-cold 0.1 M calcium chloride (10 ml). The suspension was centrifuged (4500 x g, 10 min, 
4°C) and the pellet was re-suspended in ice-cold 0.1 M calcium chloride (2 ml) followed by a 
30 min incubation on ice. These competent cells were made just before transformation for 
better efficiency. 
3.3.6.2 Transformation of the pET28a-TrxR clones 
The ligation mix (5 µl) was added to competent cells (20 µl) and incubated on ice (30 
min). This mixture was then heat shocked (42oC, 90 s) and placed directly on ice (2 min). 
Pre-warmed (37oC) SOC media (Tryptone 2% (w/v), yeast extract 0.5% (w/v),         
MgCl2 (10 mM), NaCl (10 mM), KCl (2.5 mM) and glucose (20 mM)) (80 µl) was added to 
the cells which were incubated for 1 hour at 37oC in a shaking water bath. The 
transformation mix (50 µl) was plated onto LB agar plates containing 100 µg/ml of ampicillin 
and incubated at 37oC overnight. As a control for competent cell growth, E. coli BL21 (DE3) 
competent cells were plated onto a LB agar plate (no antibiotic) whilst as a control for 
antibiotic activity, untransformed E. coli BL21 (DE3) competent cells plated onto the 
selective medium. As a control for competency, E. coli BL21 (DE3) cells were transformed 
with the pET28a expression vector (50 ng) and the transformation efficiency was calculated. 
To confirm the identity of the clones obtained, a colony PCR using the reaction conditions 
described above was done and the plasmid DNA was purified and linearized with NdeI or 
BamHI (Section 3.3.3). 
3.3.7 Induction, expression and purification of thioredoxin and TrxR 
3.3.7.1 Generating a crude extract for purification 
3.3.7.1.1 Induction and expression 
Protein expression of the pET28a clones (pMTRA, B, C and D), was induced by 
culturing selected clones in LB kanamycin (30 µg/ml) media until an OD600 of             
between 0.3-0.4 was reached. IPTG (0.5 mM) was added to cultures which were incubated at 
37oC in a shaking water bath. Following IPTG addition, samples were taken every 30 minutes 
and an OD600 measured. These samples were centrifuged (12,000 × g, 10 min, 4oC) and re-
suspended in water to a final OD600 of 10. An equal amount of treatment buffer [125mM 
Tris-HCl, 4% (m/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2- mercaptoethanol, 0.01% (m/v) 
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bromophenol blue, pH 6.8] was added to 20 µl of the re-suspended samples and the samples 
were analyzed by SDS-PAGE. 
3.3.7.1.2. Sonication 
Sonication is the use of high intensity sound waves to disrupt cells and thus allowing 
protein extraction from cells (Benov and Al-Ibraheem, 2002). Samples (OD600 of 10) were 
sonicated for 2 minutes and incubated on ice for 1 minute. This was repeated three times and 
thereafter, the samples were centrifuged (15, 000 × g, 30 min, 4oC) and the supernatant was 
stored at -20oC.  
3.3.7.2 Ni-NTA affinity purification 
Ni-NTA agarose beads (1 ml) were added and allowed to settle into a column and 
equilibrated with 5 volumes equilibration buffer (0.02 M imidazole, 0.5 M NaCl, 0.001 M 
mercaptoethanol, 0.02 M Tris-HCL (pH 8.0)). The column was incubated with the 
appropriate crude extract (thioredoxin or thioredoxin reductase) at 4°C overnight in a 
Revolver™ 360° Sample Mixer. The unbound fraction was thereafter eluted and the resin 
was washed with 10 volumes of wash buffer (0.5 M NaCl, 0.02 M Tris-HCl (pH 8.0)). Two 
volumes of elution buffer (0.25 M imidazole, 0.5 M NaCl, 0.02 M Tris-HCl (pH 8.0)) were 
then incubated with the resin (4°C, 30 min) and the bound protein was eluted and the 
resulting fractions were analyzed by SDS-PAGE (Section 2.4). The resin was then washed 
with 0.5 M NaOH for 30 min and stored in 30% (v/v) ethanol at 4°C.  
3.4 Results 
3.4.1 Cloning of thioredoxin reductase from Saccharomyces cerevisiae 
To clone the TRR1 gene, genomic DNA was isolated from S. cerevisiae using the 
Bust ‘n Grab method (Figure 3.1 A; Harju et al., 2004) and PCR amplification of the TRR1 
gene was performed using TRR1 specific primers (Figure 3.1 B). The resulting PCR 
amplicons were gel purified (Figure 3.4.1 C) and sized at the expected size of 960 bp. 
The gel purified TRR1 fragment was then ligated to the pTZ57R/T vector using the 
InsTAcloneTM PCR cloning kit and transformed into E. coli JM109 cells yielding four 
clones (pTRRA-D). Plasmid DNA from these clones was isolated using a plasmid DNA 




Figure 3.1 TA cloning of TRR1 from S. cerevisiae. Genomic DNA was isolated from S. cerevisiae 
using the Bust ‘n Grab procedure (Harju et al., 2004) (A), PCR of the DNA was undertaken using 
TRR1-specific primers and a no template control (NTC) was included to check for the presence of 
contamination (B), PCR product was gel purified using the Fermentas gel purification kit (C) and the 
plasmid DNA of the clones was isolated using the plasmid DNA purification (Section 3.3.2) (D). 
The isolated plasmid DNA from these clones was used to confirm the identities of the 
clones by using two approaches. Firstly, restriction digestion using NdeI and HindIII was 
performed using the plasmid DNA of the pTRRA-D clones to liberate the TRR1 fragment. 
This restriction digestion showed that the size of the bands obtained were 2890 bp 
(pTZ57R/T), 966 bp (TRR1 fragment) and 3823 bp (pTRRA clone without the HindIII to 
HindIII site on the pTZ57R/T vector) matched the expected band sizes 2886 bp (pTZ57R/T), 
960 bp (TRR1 fragment) and 3846 bp (pTRRA clone without the HindIII to HindIII site on 
the pTZ57R/T vector) (Fig. 3.2 A). Secondly, a PCR with TRR1-specific primers was 
performed using the pTRRA-D plasmid DNA as a template. The amplicons (966 bp) obtained 





Figure 3.2 Confirming that the pTRRA-D clones contained TRR1. The isolated pTRRA-D clones 
were restricted with NdeI and HindIII (A). In addition, PCR of the plasmid DNA was undertaken 
using TRR1-specific primers to confirm the presence of the insert and a no template control (NTC) 
was included (B). 
The expression vector, pET28a, was isolated from E. coli BL21 (DE3) cells using the 
standard plasmid DNA purification procedure (Section 3.3.2) and a double digestion with 
NdeI and HindIII was performed so that the similarly cut TRR1 fragment could be ligated 
into the expression vector (Fig. 3.3). 
 
Figure 3.3 Isolation and restriction digest of expression vector for sub-cloning. pET28a was 
isolated from E. coli BL21 (DE3) (A) and restriction digested with the NdeI and HindIII restriction 
enzymes and an uncut pET28a control was included (B).  
The gel purified TRR1 fragments and the restricted pET28a vector DNA were ligated 
using a 3:1 molar ratio of insert to vector DNA to yield the plasmids pMTRA-D. A one-hour 
ligation incubation at room temperature followed by overnight incubation at 4oC was 
sufficient for these experiments. The pMTRA-D vector DNA was then transformed into 
competent E. coli BL21 (DE3) cells (Section 3.3.6.1) and plated on LB kanamycin plates.  
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To select for clones containing pMTRA-D, single colony PCR (Section 3.3.1.2.2) was 
performed using a small fraction of the selected colonies. The results showed that the TRR1 
fragment had been successfully ligated to pET28a (Fig. 3.4 A) and a PCR was performed 
using the plasmid DNA (B) as a template. The amplicons (967 bp) obtained showed that 
TRR1 had indeed been successfully ligated into pET28a (Fig. 3.4 C). A restriction digestion 
to liberate the TRR1 fragment out of the pET28a vector (Fig. 3.4 D) was also performed and 
the sizes of the bands obtained 970 bp (TRR1 fragment) and 5370 bp (pET28a) matched the 
expected sizes 960 bp (TRR1 fragment).   
 
Figure 3.4 Confirming that the pMTRA-D clones contained TRR1. A colony PCR was performed 
using a small fraction of the single colonies and a NTC was included (A). pMTRA-D DNA was 
isolated from E. coli BL21 (DE3) cells using a plasmid DNA procedure (B). A PCR of the plasmid 
DNA was undertaken using TRR1-specific primers to confirm the presence of the insert in the plasmid 
isolations and a NTC was also included (C). Plasmid DNA of the clones was restriction digested with 
HindIII and NdeI. Control experiments included a restriction digestion with NdeI and HindIII on 





Figure 3.5 Sequence alignments of the pMTRA promoter sequences with the TRR1 sequence 
from S. cerevisiae by ClustalW2. The pMTRA-Dclones were sequenced (Central Analytical 
Facilities, Stellenbosch University) in both directions (promoter and terminal) and the 
sequence data was evaluated (Fig. 3.5). All of the four sequences were aligned to the TRR1 
sequence from the Saccharomyces Genome Database (SGD) (http://www.yeastgenome.org, 




3.4.2 Induction, expression and purification of thioredoxin reductase from the pMTRA-
D clones 
After confirmation of the identity of the pMTRA–D clones, protein expression was 
induced in these cells with IPTG. In these experiments, IPTG was added to the cultures 
(Section 3.3.7.1.1) and protein expression was monitored periodically (30-180 min). A 
comparison of the uninduced control and the induced sample showed the enhanced 
expression at 36 kDa which was close to the expected size of 35 kDa for TRR1 (Fig. 3.6). 
The maximum expression of thioredoxin reductase was observed at the 60 min interval and 
this time point was used in the purification of the protein. 
 
Figure 3.6 IPTG induced expression of the pMTRA-D clones. The clones were induced with 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for various time intervals (0-180 min). To ensure 
that an equal amount of protein was loaded into each well, samples from the induced cultures were 
diluted to an equal optical density of 10 before sample buffer was added to them. An uninduced 
control was included. 
To purify the recombinant thioredoxin reductase, transformed E. coli BL21 (DE3) 
cells were cultured and induced with IPTG (0.5 mM) for 60 min. The samples were then 
centrifuged (12,000 × g, 10 min, 4oC) and re-suspended in water to a final OD600 of 10. An 
equal amount of treatment buffer [125mM Tris-HCl, 4% (m/v) SDS, 20% (v/v) glycerol, 10% 
(v/v) 2- mercaptoethanol, 0.01% (m/v) bromophenol blue, pH 6.8] was added to 20 µl of the 
re-suspended samples (Section 3.3.7.1) and the crude extract was used for nickel affinity 
chromatography (Section 3.3.7.2). The absence of bands from the wash procedure and 
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appearance of single bands (Fig. 3.7) show successful purification of thioredoxin reductase 
with a size of 35 kDa (Fig. 3.6).  
 
Figure 3.7 Purification of recombinant thioredoxin reductase by nickel affinity 
chromatography. TRR1 was induced for 1 hour and the induced cells were treated as described in 
section 3.3.7.1 for protein purification. Samples from the wash procedure of Ni-NTA affinity 
purification were included. 
3.4.3 Induction, expression and purification of thioredoxin from the pLPTrxA/B clones 
The pLPTrxA-B clones were obtained from Miss L. Padayachee (PhD student, 
UKZN). To confirm the identity of these clones, sequence analysis (Central Analytical 
Facilities, Stellenbosch University) was also performed on them (data not shown). Following 
sequence analysis, the clones (pLPTrxA-B) were IPTG-induced at different time intervals 
(data not shown) and the optimal expression period was shown to be 6 hours. The protein was 
expressed successfully with the induced bands at a calculated size of 13 kDa which was very 





Figure 3.8 IPTG induced expression of the pLPTrxA-B clones. Clones were induced with 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) for 6 hours. To ensure that an equal amount of protein 
was loaded into each well, samples from the induced cultures were diluted to an equal optical density 
of 10 before sample buffer was added to them. The uninduced samples were included. 
Similarly as described for to the recombinant purification of thioredoxin reductase, 
transformed E. coli (DE3) cells containing the pLPTrxA-B clones was cultured and induced 
with IPTG for 6 hours as this is when optimum protein expression is observed (Padayachee, 
2013).  These samples were then treated as described above (Section 3.3.7.1) and used as 
crude extract for nickel affinity chromatography (Section 3.3.7.2). The absence of bands from 
the wash procedure and appearance of single bands (Fig. 3.9) show successful purification of 





Figure 3.9 Purification of recombinant thioredoxin by affinity chromatography. After TRX1 had 
been induced for 6 hours, the cells were treated as described in section 3.3.7.1 for protein purification. 
Samples from the wash procedure of Ni-NTA affinity purification were included. 
3.5 Discussion 
One of the major hurdles that had to be overcome in this research was acquiring pure 
thioredoxin and thioredoxin reductase which are extremely costly and we therefore chose to 
purify these proteins. In native protein purification, thioredoxin was harvested from 
supernatants of yeast cells incubated with 20% (v/v) ethanol at 37°C for 2 hours and were 
secreted directly into the medium after the incubation period (Inoue et al., 2007). This 
method could offer several advantages as opposed to conventional extraction methods. 
However, Inoue et al., (2007) utilized Western blotting instead of SDS-PAGE for their 
analysis of purified protein and studies in our lab found that the yield obtained from this 
method was very low and therefore recombinant expression was investigated (Padayachee, 
2013). On the other hand, recombinant expression, E. coli offers a means for the rapid, high 
yield production of thioredoxin system proteins.  
In this study, genomic DNA from S. cerevisiae was successfully isolated (Fig. 3.1 A) 
and the TRR1 gene was amplified (Fig. 3.1 B) and cloned into the pTZ57R/T cloning vector. 
TRR1 was then subcloned into the pET28a expression vector. The successful induction of 
thioredoxin reductase expression (Fig. 3.6) and the sequence data alignments (Fig. 3.5) proved 
that TRR1 was successfully cloned and expressed. Thioredoxin clones were acquired (as 
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mentioned in section 3.2) and tested and these were found to contain the TRX1 gene and thus 
expression was induced in these cells (Fig. 3.8). Both thioredoxin (Fig. 3.9) and thioredoxin 
reductase (Fig. 3.7) were subsequently purified using nickel affinity chromatography. The 
purified proteins were then ready to be assayed and used in our kinetic analysis. 
Future studies could use of high-cell-density protein expression methods including 
auto-induction introduced by Studier (2005) or a high-cell-density IPTG-induction method 
(Sivashanmugam et al., 2009). With the latter method, 14–25 mg of NMR triple-labeled 
proteins and 17–34 mg of unlabeled proteins from a 50 mL cell culture was easily obtainable 
and this high protein yield used the same recombinant DNA constructs, bacterial strains and a 
regular incubator shaker (Sivashanmugam et al., 2009). In the former method, high-density 
protein expression was achieved by simply inoculating a suitable auto-inducing medium from 
a seed culture and growing to saturation. This produced much higher levels of target protein 
per volume of culture compared to IPTG or other inducer dependent expression (Studier, 




Chapter 4: THIOREDOXIN DEPENDENT REACTIONS ARE 
INTERCONNECTED? 
4.1 Introduction 
The main aim of this study was to determine the interconnectivity of thioredoxin 
dependent reactions. In previous computational modeling studies, it was shown that changes 
in the activity of some reactions affected the fluxes of other reactions in the thioredoxin 
system (Pillay et al., 2011). However, as stated in chapter 1, these results were obtained 
solely from computational analysis and it is not known whether the system displays this 
behaviour in vitro and in vivo. Thus, to confirm these computational results, the system was 
analysed in vitro. As a first step to describe the connectivity between thioredoxin-dependent 
reactions precisely, a reaction scheme describing the oxidation of thioredoxin by two 
substrates and its subsequent reduction by thioredoxin reductase was developed and analyzed 
in this study (Fig. 4.1).  
 
Figure 4.1 Reaction scheme of the proposed thioredoxin competition assay. The reduced 
thioredoxin, Trx (red), directly interacts with oxidized proteins Insulin (ox) and IgY (ox) by reducing 
disulfide bridges. As a result, the target protein is reduced (Insulin (red)) and IgY (red) and 
thioredoxin itself is oxidized (Trx (ox)). The regeneration of thioredoxin from its oxidized form is 
catalyzed by thioredoxin reductase (TR) using NADPH. 
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For this assay, two substrates of thioredoxin had to be obtained. In previous kinetic 
assays, it was shown that the DTT-dependent reduction of insulin increased in the presence of 
thioredoxin, suggesting that Trx catalysed the rate of insulin reduction (Holmgren, 1979). 
This reduction of insulin by the thioredoxin system can be measured in two ways. Firstly, the 
rate of NADPH oxidation can be monitored by the decrease in absorbance at 340 nm 
(Holmgren, 1979). As the reduction reaction proceeds, a white precipitate is formed mainly 
from the free insoluble β-chains of insulin which allows for a second method to determine 
thioredoxin system activity (Holmgren, 1979). The formation of that precipitate causes 
turbidity in the mixture which can be recorded spectrophotometrically at 650 nm (Holmgren, 
1979).  
The competing substrate used in this study, immunoglobin Y, was chosen as it contains 
disulfide bonds (Fig. 4.2) and is readily obtained (Pürzel et al., 2009). Although this substrate 
had never been tested before, it was expected that thioredoxin would also have a similar 
reducing activity on IgY. 
 
Figure 4.2 Structure of a typical immunoglobulin (antibody) protein. Two identical heavy chains 
are connected by disulfide linkages (Gilbert, 2010). 
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Like other immunoglobins, IgY is a Y-shaped molecule (Fig. 4.2) that consists of two 
identical heavy chains and two identical light chains which are connected by disulfide bonds 
(Woof and Burton, 2004). It is a major antibody found in birds, reptiles and lungfish blood 
(Leslie and Clem, 1969). However, for the purpose of this study, IgY was isolated from 
chicken egg yolks as they were easily obtainable. 
 The effect of IgY reduction by thioredoxin was also to be determined in a similar 
fashion to that of insulin by monitoring NADPH oxidation at 340 nm. However, if IgY 
oxidation did not result in turbidity, then it would be possible to monitor the overall flux in 
the system through NADPH oxidation at 340 nm and the reduction of insulin specifically at 
650 nm. Thus, if IgY acted as a competitive inhibitor for insulin reduction, then the rate of 
turbidity at 650 nm should decrease with increasing IgY concentrations.   
4.2  Materials and methods 
4.2.1 Materials 
Dithiothreitol (DTT), human recombinant insulin, 5, 5'-dithiobis (2-nitrobenzoic acid) 
(DTNB), β-nicotinamide adenine dinucleotide phosphate (NADPH), bovine serum albumin 
(BSA) were obtained from Sigma (Capital Labs, South Africa). Polyethylene glycol (PEG) 
20,000 was obtained from Merck (South Africa) and all other common reagents were 
obtained from Saarchem (Merck, South Africa).  
4.2.2 Preparation of reagents 
4.2.2.1 Human recombinant insulin [1.6 mM] 
A stock solution of insulin was prepared by dissolving insulin (50 mg) in 0.5 ml of 
100 mM potassium phosphate buffer (pH 6.5). The pH was adjusted to 2-3 with 1 M HCl and 
thereafter titrated back to the original pH of the buffer (pH 6.5) with NaOH (1 M). The 
volume was then adjusted to 5 ml with dH2O and the solution was stored at – 20°C. 
4.2.2.2 DTNB [63.1 mM] 
A stock solution of DTNB was prepared (before use) by dissolving DTNB powder 
(0.025 g) in 99% ethanol (1 ml).  
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4.2.2.3  DTT [1 M] 
A stock solution of DTT was prepared at the time of use by dissolving DTT powder 
(0.154 g) in dH2O (500 µl). This solution was then made up to 2 ml with dH2O and used in 
the thioredoxin activity assay. 
4.2.2.4  NADPH [50 mM] 
NADPH (10 mg) was stored in 1.5 ml microcentrifuge tubes at -20°C. Before use, 
dH2O (250 µl) was added to a single tube. The stock solution was stored at-20°C. 
4.3  Methods 
4.3.1 Computational modeling 
Kinetic parameter sets for the yeast thioredoxin system were obtained from the 
BRENDA database (Chang et al., 2009), published literature and from our laboratory       
(Pillay et al., 2011) and were used to build the computational model in Python Simulator for 
Cellular System (PySCeS) (http://pysces.sourceforge.net). The system was modeled using 
realistic kinetic parameters and rate expressions (Pillay et al., 2013). In the model, 
thioredoxin reductase was modeled with Michaelis-Menten kinetics, while IgY and insulin 
reduction reactions were described using mass action kinetics (Appendix 1) (Pillay et al., 
2009). 
In order to analyze the behavior of the system, a set of parameters and species 
concentrations resembling the in vitro reaction conditions (Table 4.1) were utilized and the 
data was plotted in double log space and linear space. 
4.3.2 Isolation of immunoglobin Y (IgY) 
The egg white and yolk were separated by carefully washing the egg yolk under 
running water. The yolk sac was punctured and yolk volume was determined in a measuring 
cylinder. The yolk sac was discarded and two volumes of 100 mM phosphate buffer, pH 7.6 
containing 0.02% (w/v) sodium azide were added to the yolk and mixed thoroughly using a 
glass rod. A sample (50 μl) was taken at this stage and PEG (3.5% (w/v)) was added and 
mixed until the PEG had completely dissolved. The sample was centrifuged (4,420 × g for 20 
min at room temperature). The supernatant was filtered through absorbent cotton wool which 
was placed at the base of a funnel noting that the filtrate must be a clear yellow liquid. If the 
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filtrate was not clear, the filtration step was repeated. The filtrate volume was recorded and 
another sample (50 μl) was removed. Thereafter, PEG concentration was increased to 12% 
and completely dissolved. The resulting mixture was centrifuged (12,000 × g for 10 min at 
room temperature) and a further sample (50 μl) was taken from the supernatant. The 
remaining supernatant was discarded and the pellet was dissolved in a volume of phosphate 
buffer equal to the original egg yolk volume. PEG was added to a final concentration of 12% 
(w/v) and the dissolved thoroughly. This mixture was then centrifuged (12,000 × g for 10 min 
at room temperature) and a sample (50 μl) was taken from the supernatant before discarding. 
The pellet was resuspended in phosphate buffer to a ⅙ of the original egg yolk volume and a 
final sample was taken and the purified IgY was then stored at -20oC. 
4.3.3 Thioredoxin activity 
To determine the activity of our purified thioredoxin, the change in absorbance at    
650 nm was directly monitored and the sample without the addition of the purified 
thioredoxin was used as the reference cuvette (blank). The reaction was initiated by the 
addition Trx (1.5 µM) to give a final volume of 1 ml for the reaction. The final reaction 
mixture contained insulin (0.01 mM), 63 mM potassium phosphate buffer (pH 7.0), EDTA 
(2 mM), Trx (1.5 µM) and DTT (1 mM). The absorbance measurements were recorded by the 
UV-1800 Shimadzu Spectrophotometer for 15 minutes following a 10 minute incubation 
period at 25oC (Padayachee, 2013).  
4.3.4 Thioredoxin reductase activity 
The DTNB reducing activity of our purified thioredoxin reductase was determined in 
the presence of DTNB as a substrate by monitoring change in absorbance at 412 nm. This 
assay was done in the presence of univalent cations (NaCl) to increase the rate (Lim and Lim, 
1995). The reaction mixture contained 0.1 M Tris-Cl (pH 8.0), 0.5 mM DTNB, 0.24 mM 
NADPH, 0.01% BSA and 0.5 M NaCl in a final volume of 1 ml. The reaction was started by 
the addition of the purified thioredoxin reductase (0.2 µM) and the change in absorbance was 
monitored at 412 nm. Absorbance measurements were recorded by the UV-1800 Shimadzu 





Table 4.1 Species concentrations and kinetic parameters used in the model 
Species  Value References 
NADPH  400 µM This study 
NADP  4 µM This study 
TrxSS  1.5 µM This study 
TrxSH  1.5 µM This study 
InsOx  10 µM This study 
InsRed  2 µM This study 
IgYOx  10µM This study 
IgYRed  2 µM This study 
Parameters  Thioredoxin Reductase  
[TR]  0.1 µM This study 
kcat  43.7 s-1 Oliveira et al., 2010 
Knadph  1.2 µM Williams, 1976 
Ktrxss  2.8 µM  Williams, 1976 
k2  1 μM-1s-1 Estimated 
k3  1 μM-1s-1 Estimated 
4.3.5 IgY reduction by thioredoxin 
To prove that thioredoxin can reduce IgY disulfide bonds we used the thioredoxin 
activity assay (Holmgren, 1979). In this assay, the reaction mixture contained 2 mM EDTA, 
100 mM potassium phosphate buffer (pH 7.0), 0.4 mM NADPH, 1.5 µM thioredoxin, 
thioredoxin reductase (0.1 µM) and IgY (10 µM) to the final volume of 0.5 ml. The reaction 
was initiated by the addition of IgY and the rate of NADPH oxidation was measured by the 
decrease in absorbance at 340 nm by the UV-1800 Shimadzu Spectrophotometer for              
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5 minutes. A sample without the addition of IgY was used as the reference cuvette (blank). 
As a control experiment, to verify that the reduction of IgY disulfide bonds would not cause 
interference in the kinetic analysis of the thioredoxin activity assay (Section 4.3.3), the 
absorbance at 650 nm was also monitored. In this experiment, the reaction mixture contained 
IgY (0.01 mM), 63 mM potassium phosphate buffer (pH 7.0), EDTA (2 mM), Trx (1.5 µM) 
and DTT (1 mM) in a final volume of 0.5 ml. The reaction was also initiated by the addition 
of IgY and the change in absorbance was measured at 650 nm by the UV-1800 Shimadzu 
Spectrophotometer for 5 minutes. Similarly, a sample without the addition IgY was used as 
the reference cuvette (blank).  
4.3.6 Competition assay 
In the competition assay (Fig. 4.2), IgY was expected to act as a competitive substrate 
for thioredoxin. The rate of NADPH consumption for insulin (control experiment) and IgY 
reduction were followed at 650 nm by the UV-1800 Shimadzu Spectrophotometer for 5 min 
at 25oC. The reaction mixture contained 2 mM EDTA, 100 mM potassium phosphate buffer 
(pH 7.0), 0.4 mM NADPH, 1.5 µM thioredoxin, insulin (10 µM), IgY (0-30 µM) and 
thioredoxin reductase (0.1 µM) in a final volume of 0.5 ml. As a positive control in the 
experiment, to verify that components such as the buffer, NADPH, Trx and thioredoxin 
reductase were functional, insulin (10 µM) was used as the only substrate and a reference 
cuvette without the addition of any substrate (IgY/Insulin) was used as the blank. 
4.4 Results 
4.4.1 Computational modeling 
The yeast thioredoxin system was computationally modeled (Appendix 1) in order to 
study the interconnectivity between thioredoxin-dependent reactions. To analyze this system, 
IgY was varied and the effect of this change on the fluxes through the thioredoxin system was 
determined and plotted below. The computational data showed that the steady state flux of 
insulin reduction and that of IgY reduction affected each other (Fig. 4.3). For a given insulin 
concentration, the addition of IgY to the system at 10 µM (red), 20 µM (blue) and 30 µM 
(green), reduced the flux of the insulin reduction reaction (Fig. 4.3 A and B) in a 




Figure 4.3 Thioredoxin-dependent reactions can affect each other. In each of these simulations, 
the steady state flux of the thioredoxin-dependent reduction of insulin at varying concentrations (IgY) 
is shown. IgY was varied from 10 µM (red), 20 µM (blue) and 30 µM (green). The steady state fluxes 
of insulin reduction (A and B) and IgY reduction (C and D) were monitored. Fig. 4.3 A and C were 
plotted in linear space while Fig. 4.3 B and D were plotted in double log space to show scaled changes 
in the flux (Pillay et al., 2013).  
At higher concentrations of insulin, the IgY was outcompeted and the reactions 
approached the same limiting rate. Similarly, an increase in insulin concentration decreased 
the flux of the IgY reduction reaction (Fig. 4.3 C and D). 
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4.4.2 In vitro analysis 
 
Figure 4.4 Confirming the activity of the purified thioredoxin and thioredoxin reductase. A) 
typical turbidimetric curves upon addition of S. cerevisiae thioredoxin (1.5 μM) are shown, in 
comparison to turbidity formed in the no thioredoxin control with addition of DTT only (blue). In B) 
the colorimetric linear relationship between absorbance at 412 nm and time, for the reduction of 
DTNB (0.5 mM) by S. cerevisiae thioredoxin reductase (0.2 µM) are shown, in comparison to the 
color change upon exclusion of thioredoxin reductase in the reaction mix (blue). Experiments were 
performed in duplicate. 
A thioredoxin activity assay was utilized to confirm activity of the purified 
thioredoxin by the change in absorbance at 650 nm (Holmgren, 1979). It was evident from 
the rates of insulin reduction obtained (7.5 × 10-5 ∆A650/min) that the purified thioredoxin 
samples were active. The reduction of DTNB was used to measure the purified thioredoxin 
reductase activity by the change in absorbance at 412 nm (Lim and Lim, 1995). It was also 
evident by the rates of DTNB reduction obtained (2.33 × 10-3 ∆A412/min) that the purified 




Figure 4.5 IgY was a substrate for the thioredoxin system. As a positive control A) NADPH 
consumption was determined by the decrease of absorbance at 340 nm during the initial linear phase 
as insulin (10 µM) was reduced (red and green) using the sample without addition of insulin as a 
control (blue). In B) NADPH consumption was also determined from the decrease in absorbance at 
340 nm as IgY was reduced (red and green) using the sample without addition IgY (10 µM) as a 
control (blue). Experiments were performed in duplicate and proceeded at 25°C. 
The next step was to prove that IgY could be used as a substrate for thioredoxin. As a 
positive control, insulin reduction by the thioredoxin system was carried out. The rate of 
NADPH oxidation was measured and found to be 6.50 × 10-4 ± 0.01 ∆A340/min (Table 4.2). 
Similarly, to test NADPH oxidation using IgY as a substrate, the same experiment was 
undertaken using IgY as a substrate and the data indicated that IgY disulfides were rapidly 
reduced causing the reaction to stop after 100 seconds (Fig. 4.5 B). Evidently, IgY could be 
used as a substrate of the thioredoxin system as the rate of NADPH oxidation was found to be 
in the same range as insulin (Table 4.2).  
Table 4.2 Comparison of the rates of NADPH oxidation using insulin and IgY as substrates 
Substrate Rate (A340/min) Standard error Percentage error 
Insulin (10 µM)   6.50 × 10-4 0.01 6.14 
Immunoglobin Y (10 µM) 5.10 × 10-4 0.01 8.20 
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 To ensure that IgY reduction by thioredoxin would not cause interference in the 
insulin turbidity assay at 650 nm, we analysed the reduction of IgY catalysed by thioredoxin.  
 
Figure 4.6 IgY reduction does not affect the absorbance at 650 nm. A turbidimetric assay upon 
addition of S. cerevisiae thioredoxin (1.5 μM) with varying IgY concentrations (10 μM 
purple; 20 μM green; 30 μM red) was compared to a reaction mixture without IgY (blue).  
There was no change of absorbance at 650 nm with 1.5 μM thioredoxin and 1 mM DTT at 
pH 7.0 over increasing IgY concentrations (0 - 30 μM). Thus, IgY in its oxidized or reduced 
form does not absorb significantly at 650 nm therefore we expected that if the competition 
assay was monitored at this wavelength, it would be specific for insulin. 
In order to investigate the behaviour of the thioredoxin system with two substrates, 
the rate of insulin precipitation in the presence of IgY was monitored at 650 nm. As a control, 
the rate of reduction by the thioredoxin system with insulin alone was monitored and was not 
affected in these assays (Fig. 4.7 A-D (red)). Different concentrations of IgY where tested in 
duplicate in this assay at 10 µM (Fig. 4.7 A), 20 µM (Fig. 4.7 B) and 30 µM (Fig. 4.7 C) 
























 The initial rates were then analysed and one was found to be different within the 
initial phase of the assay. The rates with 10 µM and 30 µM of IgY showed a 10-fold change 
while the 20 µM IgY reaction mixture showed no change from the reaction with insulin only 
(Table 4.3). However, the reaction with 20 µM IgY had the highest rate of all the IgY 
containing reactions (10 µM and 30 µM). These enigmatic results suggest the requirement of 
more replications in the assay. Further, although there appeared to be a difference in initial 
rates, an additional pattern was observed in the assay. Following the expected linear increase 
in precipitation, a concentration-dependent decrease in absorbance was observed. Thus, the 
more IgY was added to the assay, the faster the precipitation occurred thus resulting in the 
decrease in absorbance at 650 nm (Fig. 4.7 D). This was an unexpected result and suggested a 
possible interaction between the substrates in the system.  
 
Figure 4.7 Competition assay for thioredoxin reduction. In each of these graphs the reaction of 
thioredoxin reduction of the substrate insulin (red) at varying concentrations of IgY is shown. 
Duplicate IgY-Insulin assays at varying IgY concentrations from 10 µM (A), 20 µM (B) and 30 µM 
(C) (green and purple) were performed with a no substrate blank (blue) included. In D) an overall 
presentation of the competition assay is shown at 25°C and was monitored at 650 nm.  
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 Additionally, a t-test was performed to analyse if there is a significant difference in 
rates when IgY concentration was increased. The critical level was set at                             
0.05 (critical p-value) and the change in rates for 10 µM and 20 µM IgY were found to be 
insignificant as t was bigger than 0.05 for both concentrations (Table 4.3). However, the 
change was found to be statistically significant for the 30 µM IgY sample as t was found to 
be smaller than 0.05 (Table 4.3). These statistical results also suggested the need for more 
replications in the competition assay.     
Table 4.3 Comparison of the rates of NADPH oxidation using insulin and insulin and/IgY as 









Insulin 1.00 × 10-3   1.00 × 10-3  1.00 × 10-3 
Insulin and IgY 9.40 ± 0.02× 10-4  1.10 ± 0.05× 10-3  4.90 ± 0.07× 10-4  
t-test (critical p-value = 0.05) 
Immunoglobin Y 10 µM 20 µM 30 µM 
t Stat -0.060 1.244 2.987 
P(T<=t) one-tail 0.476 0.112 0.004 
P(T<=t) two-tail 0.953 0.223 0.007 
    
4.5 Discussion 
An assay based on the DTT-dependent reduction of insulin by thioredoxin was used to 
determine the activity of the purified thioredoxin (Holmgren, 1979b). While, the activity of 
thioredoxin reductase was assayed using 5,5'-dithiobis-2-nitrobenzoic acid (DTNB). This assay 
enabled the examination of the activity purified thioredoxin reductase in the absence of 
thioredoxin. Lim and Lim (1995) showed that the use of univalent cations such as sodium 
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chloride in the thioredoxin reductase activity assay significantly increased the rate of reduction 
of DTNB. Once it was confirmed that the purified thioredoxin and thioredoxin reductase were 
active (Fig. 4.3), the next step involved analysis of the system with two substrates first 
computationally and in vitro by a novel competition assay.  
Our computational modelling analysis confirmed that an increase in concentration of 
one of the substrates in the thioredoxin system decreased the flux of another thioredoxin 
oxidation reaction (Fig. 4.3). In our in vitro analysis, we used the standard insulin reduction 
assay for thioredoxin activity with two substrates (IgY and insulin). Our results showed that 
an increase in one substrate concentration could affect the rate of another thioredoxin 
oxidation reaction at higher concentrations of IgY (Table 4.3). However, the results were 
enigmatic as an increase in IgY concentration resulted in an unexpected decrease in 
absorbance at 650 nm (Fig. 4.6 D). This result could have been due to the exceptional rate of 
IgY reduction (Fig. 4.4 B) and the possible interaction between the two substrates in the 
assay (below).  
IgY reduction by the thioredoxin system occurred rapidly within the first 100 seconds 
as measured by NADPH oxidation (Fig. 4.4 B), before turbidity was visible in the 650 nm 
assay (Fig. 4.6). Thus, it is possible that the statistically weak effects of IgY on the rate of 
insulin reduction (Table 4.3) could be due to the fact that IgY was already reduced 
completely. Therefore, the use of a higher IgY concentration would be recommended for a 
more accurate analysis of the competition assay as there would still be IgY available to be 
reduced after the first 100 seconds of the assay. The unexpected decrease in absorbance 
observed in this assay could be due to IgY increasing the rate of insulin precipitation. This 
effect was previously demonstrated in experiments by Cantrell et al. (1972) who showed that 
a polymer of denatured insulin is formed which is capable of binding to IgG 
(immunoglobulin similar to IgY) in a way that produces a complement-fixing aggregation of 
IgG. Although the chemical nature of this insulin-IgG interaction is unknown, the partial 
dissociation observed with immunoelectrophoresis following solubilization suggested a non-
covalent interaction (Cantrell et al., 1972). These results showed that the precipitate 
composition was approximately 80% insulin and 20% IgG which emphasized that IgG was a 
co-precipitant of insulin and our data also suggests that IgY is a potent insulin co-precipitant.  
Several investigators found that complexes of insulin and IgG were formed when 
exogenous insulin was administered to patients with anti-insulin antibodies (Abrass et al., 
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1983). These complexes of insulin and IgG contributed to an increased load of circulating 
immune complexes in patients with diabetes mellitus and offered a possible explanation for 
the presence of these components in microangiopathic lesions and may be a contributing 
factor to the pathogenesis of diabetic microangiopathy (Farquhar and Palade, 1962). 
Interestingly, insulin aggregation has been previously investigated. The proposed mechanism 
included insulin’s self-association into dimers and hexamers, the interactions with 
hydrophobic surfaces and formation of stable intermediate species which could interact with 
other present molecules (Jeffrey et al., 1976). Insulin aggregation is observed under 
conditions such as neutral pH, mild agitation, slightly elevated temperature (which are similar 
to conditions in the competition assay) and mild reducing conditions which lead to 
denaturation and precipitation (Brange et al., 1987). This was subsequently accompanied by 
exposure of hydrophobic groups resulting in unstable conformations which seek to minimize 
their surface energy by interacting with other unfolded molecules (Joly, 1965). This 
phenomenon could explain the possible interaction between the two substrates in the assay 
leading to rapid precipitation followed by a decrease in absorbency at 650 nm. Collectively, 
our analysis showed that there was a complex interaction between thioredoxin oxidation 
reactions, suggesting that our competition assay requires improvement, especially with 
respect to IgY concentration and more replications. In addition, the use of a different 











Chapter 5: GENERAL DISCUSSION 
The thioredoxin system is essential for maintaining the cellular redox status and plays an 
important role in a variety of cellular functions (Toledano et al., 2007). However, elevated 
levels of this system have been associated with certain diseases including HIV, malaria and 
cancer. Therefore it is evident that the construction of kinetic models is necessary to 
understand how complex networks such as the thioredoxin system can be regulated (Pillay et 
al., 2013). Hence computational modeling approaches were used in this study to develop a 
model of the yeast thioredoxin system to investigate the connectivity in thioredoxin oxidation 
reactions. To confirm the in silico analysis, in vitro kinetic analyses were planned using a 
novel competition assay. In order to achieve this, yeast thioredoxin and thioredoxin reductase 
needed to be cloned, expressed and purified (Chapter 3). 
The thioredoxin system was isolated from S. cerevisiae, cloned and expressed in        
E. coli and subsequently purified using nickel affinity-chromatography (Chapter 3). 
S. cerevisiae was chosen to study the thioredoxin system due to its ability to be genetically 
and biochemically manipulated and the availability of mutants lacking components of the 
system (Grant, 2001, Wheeler and Grant, 2004). Thus the in vitro results obtained in this 
study could be followed up in vivo. 
As a first step, it was important to make use of cheap activity assays for both 
thioredoxin and thioredoxin reductase that did not require the use of its counterpart. In order 
to detect the activity of thioredoxin reductase, an assay utilizing univalent cations in the 
reaction mixture to increase the rate of DTNB reduction by thioredoxin reductase was chosen 
(Lim and Lim, 1995). To detect thioredoxin activity, the DTT-dependent reduction of insulin 
was utilized (Chapter 4). The use of DTT, instead of thioredoxin reductase and the inclusion 
of a preincubation step to reduce thioredoxin with DTT, made this assay substantially cheaper 
(Padayachee, 2013).  
Computational modeling was used to study interconnectivity between thioredoxin-
dependent reactions by varying IgY and analyzing the effect of this change on the fluxes 
through the thioredoxin system. These results showed that the steady state flux of insulin 
reduction should be affected by increases in the IgY concentration in a concentration-
dependent manner (Chapter 4). To confirm these computational findings, in vitro kinetic 
analyses were undertaken using the insulin assay (Holmgren, 1979). Through these analyses, 
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a number of technical goals were achieved. This study showed that IgY can be used as a 
substrate for thioredoxin and this was demonstrated by the apparent NADPH oxidation at 340 
nm with IgY (Fig. 4.4 B). Furthermore, IgY was an excellent substrate as its reduction 
reaction proceeded at a comparable rate to that of insulin (Table 4.2). In our assays, the 
thioredoxin dependent reduction of IgY was complete in 100 seconds (Fig. 4.5 B) compared 
to insulin reduction that still proceeded beyond 100 seconds (Fig. 4.5 A). 
However, our in vitro kinetic analyses results were not completely convincing. 
Although IgY appeared to be a thioredoxin substrate there were some complications in the 
competition assay. IgY concentrations of 10-20 µM had contradictory or small effects on the 
rate on insulin reduction. However at 30 µM IgY, a significant decrease in the rate of insulin 
reduction was observed. These results suggested that the IgY could have been completely 
reduced before insulin aggregation was detected at 650 nm. Furthermore, this reduction of 
IgY appeared to enhance insulin aggregation which increased the rate of precipitation and 
thus decreased the absorbency at 650 nm. These unexpected results suggest that a higher 
concentration of IgY is required in order to further analyse competing thioredoxin substrates 
in vitro. Alternatively, substrates such as ribonuclease, peroxiredoxin, or aconitase B could be 
tested as competing substrates in this assay. An advantage of using these substrates is that 
their activity could be measured as well (Yamazaki et al., 2004). 
 In summary, these findings serve as an important starting point in the understanding 
of how thioredoxin-dependent reactions are connected to one another and how this 
connection affects regulation within the system. Further, this work may force a rethink about 
drugs that target the thioredoxin system as competing effects may change the active 
concentration of inhibitors needed for effective therapy. Hopefully, the development of 
smarter and more effective drug design strategies could lead to significant advances in the 
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FIX: NADPH NADP InSH InSS IgYSS IgYSH  
R1: NADPH + TrxSS = NADP + TrxSH 
(kcat1*TR*(NADPH/Knadph)*(TrxSS/K1trxss))/((1+NADPH/Knadph)*(1+TrxSS/K1trxss)) 
R2: TrxSH + InSS = TrxSS + InSH 
k2*TrxSH*InSS 
R3: TrxSH + IgYSS = TrxSS + IgYSH 
k3*TrxSH*IgYSS  
#Species (µM) 
NADPH = 400 
NADP = 4 
InSH = 10 
InSS = 2 
TrxSH = 1.5 
TrxSS = 1.5 
IgYSS = 10 
IgYSH = 2 
# Rate parameters 
 kcat1 = 43.7 s-1  
TR = 0.1 µM 
Knadph = 1.2 µM  
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K1trxss = 2.8 µM   
 k2 = 1 
 k3 = 1 
 
